- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
New study finds antidepressants have similar efficacy
Antidepressants have similar efficacy but differing side effects, according to new findings released by AHRQ. Authors of a comparative review analyzed the risks and benefits of a dozen second-generation antidepressants by examining 293 published studies and found that, overall, they led to similar rates of improvement: 54% had partial improvement, and 38% saw no improvement. On average, 61% of patients experienced at least one side effect. Venlafaxine showed a higher incidence of nausea and vomiting than the SSRIs, sertraline was more likely to cause diarrhea than some others, mirtazapine led to higher weight gain, and trazodone caused more sleepiness. Paroxetine and venlafaxine had the highest rates of discontinuation syndrome, and fluoxetine had the lowest. Bupropion was less likely to cause sexual dysfunction than some others and paroxetine was associated with higher rates.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Pharmaceutical Compounding, Storage of Faricimab Preserves Stability, Binding Properties
November 28th 2023Maintaining the structure and function of antibody biologics like faricimab is critical for their administration via intravitreal injection (IVI), a common treatment approach for retinal diseases.
